



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/018670

(22) International Filing Date:
06 March 2024 (06.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/488,736 06 March 2023 (06.03.2023) US

(71) Applicant: **CHROMA MEDICINE, INC.** [US/US]; 201 Brookline Avenue, Suite 1101, Boston, MA 02215 (US).

(72) Inventors: **ABUBUCKER, Noorussahar**; C/o Chroma Medicine, Inc., 201 Brookline Avenue, Suite 1101, Boston, MA 02215 (US). **FRIEDLAND, Ari**; C/o Chroma Medicine, Inc., 201 Brookline Avenue, Suite 1101, Boston, MA 02215 (US). **MAEDER, Morgan**; C/o Chroma Medicine, Inc., 201 Brookline Avenue, Suite 1101, Boston, MA 02215 (US). **MYER, Vic**; C/o Chroma Medicine, Inc., 201 Brookline Avenue, Suite 1101, Boston, MA 02215 (US). **TREMBLAY, Frederic**; C/o Chroma Medicine, Inc., 201 Brookline Avenue, Suite 1101, Boston, MA 02215 (US). **MOR-**

RISON, Mary, Shirley; C/o Chroma Medicine, Inc., 201 Brookline Avenue, Suite 1101, Boston, MA 02215 (US).

(74) Agent: **WEEKS, Anne, E.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF PCSK9 EXPRESSION




FIG. 21A

(57) Abstract: This application relates to compositions and methods comprising epigenetic editors for epigenetic modification of PCSK9, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by the epigenetic editors.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*